Aktis Oncology

Aktis Oncology

Biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor investor

€0.0

round
investor investor investor investor investor investor investor

€0.0

round
investor investor investor investor investor investor

€0.0

round
investor

€0.0

round
*

$175m

Series B
Total Funding000k
Notes (0)
More about Aktis Oncology
Made with AI
Edit

Aktis Oncology is a pioneering biotech company focused on developing novel radiotherapies for cancer patients with unmet medical needs. Operating in the oncology market, Aktis targets a broad set of commonly occurring cancers, aiming to revolutionize cancer treatment by putting solid tumors into remission. The company serves patients who have limited treatment options, providing them with innovative therapeutic solutions.

Aktis Oncology's business model revolves around the research, development, and commercialization of transformative cancer therapies. The company generates revenue through the development and licensing of its proprietary radiotherapy molecules, as well as potential partnerships with pharmaceutical companies. By focusing on groundbreaking science and clinical development, Aktis aims to bring new hope to cancer patients worldwide.

Keywords: radiotherapies, cancer treatment, solid tumors, oncology, biotech, unmet needs, innovative therapies, clinical development, proprietary molecules, partnerships.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo